Difference between revisions of "Residual cancer burden index"
Jump to navigation
Jump to search
(Created page with "'''Residual cancer burden index''', abbreviated '''RCB''', is an empirical predictor of outcome in breast cancer in the post-neoadjuvant therapy setting.<ref>{{cite jo...") |
|||
| (7 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
'''Residual cancer burden index''', abbreviated '''RCB''', is an empirical predictor of outcome in [[breast cancer]] in the [[post-neoadjuvant therapy]] setting.<ref>{{cite journal |authors=Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JM, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF |title=Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients |journal=Lancet Oncol |volume=23 |issue=1 |pages=149–160 |date=January 2022 |pmid=34902335 |doi=10.1016/S1470-2045(21)00589-1 |url=}}</ref> | '''Residual cancer burden index''', abbreviated '''RCB''', is an empirical predictor of outcome in [[breast cancer]] in the [[post-neoadjuvant therapy]] setting.<ref>{{cite journal |authors=Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JM, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF |title=Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients |journal=Lancet Oncol |volume=23 |issue=1 |pages=149–160 |date=January 2022 |pmid=34902335 |doi=10.1016/S1470-2045(21)00589-1 |url=}}</ref> | ||
==Definition== | |||
The [[RCB index]] is defined as:<ref name=pmid17785706>{{cite journal |authors=Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L |title=Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy |journal=J Clin Oncol |volume=25 |issue=28 |pages=4414–22 |date=October 2007 |pmid=17785706 |doi=10.1200/JCO.2007.10.6823 |url=}}</ref> | |||
:<math>RCB = 1.4 \ ( f_{inv} \ d_{prim} )^ {0.17} + \lbrack{ \ 4 \ (1 - 0.75^{LN}) d_{met}} \rbrack ^{0.17}</math> | |||
Where: | |||
:<math>f_{inv} = \text {portion of tumour bed that is viable invasive tumour}</math> | |||
:<math>d_{prim} = \sqrt {d_1 \ d_2}</math> | |||
:<math>\text{LN} = \text {number of lymph nodes with metastatic carcinoma}</math> | |||
:<math>d_{met} = \text {diameter of the largest lymph node metastasis}</math> | |||
The inputs to <math>d_{prim}</math> are: | |||
:<math>d_1 = \text{first in-plane tumour dimension}</math> | |||
:<math>d_1 = \text{second in-plane tumour dimension}</math> | |||
==Interpretation== | |||
The original paper stratified patients into three groups using two cut-points:<ref name=pmid17785706/> | |||
*Low risk (RCB-I): RCB > 0 and < 1.36. | |||
*Intermediate risk (RCB-II): RCB > 1.36 and < 3.28. | |||
*High risk (RCB-III): RCB > 3.28. | |||
If one includes the group without any residual disease, there are four groups: RCB-0, RCB-I, RCB-II, RCB-III. | |||
==See also== | |||
*[[Neoadjuvant therapy]]. | |||
*[[Lung cancer after neoadjuvant therapy]]. | |||
==References== | ==References== | ||
{{Reflist|1}} | {{Reflist|1}} | ||
==External links== | |||
*[https://www3.mdanderson.org/app/medcalc/index.cfm?pagename=jsconvert3 Online calculator for RCB index (mdanderson.org)]. | |||
[[Category:Breast pathology]] | [[Category:Breast pathology]] | ||
Latest revision as of 00:11, 16 October 2024
Residual cancer burden index, abbreviated RCB, is an empirical predictor of outcome in breast cancer in the post-neoadjuvant therapy setting.[1]
Definition
The RCB index is defined as:[2]
Where:
The inputs to are:
Interpretation
The original paper stratified patients into three groups using two cut-points:[2]
- Low risk (RCB-I): RCB > 0 and < 1.36.
- Intermediate risk (RCB-II): RCB > 1.36 and < 3.28.
- High risk (RCB-III): RCB > 3.28.
If one includes the group without any residual disease, there are four groups: RCB-0, RCB-I, RCB-II, RCB-III.
See also
References
- ↑ Yau C, Osdoit M, van der Noordaa M, Shad S, Wei J, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, López-Tarruella S, Boughey JC, Goetz MP, Hoskin T, Gould R, Valero V, Edge SB, Abraham JE, Bartlett JM, Caldas C, Dunn J, Earl H, Hayward L, Hiller L, Provenzano E, Sammut SJ, Thomas JS, Cameron D, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, van 't Veer LJ, Esserman LJ, Symmans WF (January 2022). "Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients". Lancet Oncol 23 (1): 149–160. doi:10.1016/S1470-2045(21)00589-1. PMID 34902335.
- ↑ 2.0 2.1 Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L (October 2007). "Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy". J Clin Oncol 25 (28): 4414–22. doi:10.1200/JCO.2007.10.6823. PMID 17785706.